A cancer injection used in the UK’s National Health Service (NHS) eradicated tumours in “unprecedented” trial results.
Patients who had failed to respond to any treatment after their cancer returned were offered the injection, called amivantamab.
Researchers found the jab, which was used on 102 patients with head and neck cancers, shrank the tumours in more than a third of patients and eradicated them in 15 patients.
Prof Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR) and a consultant oncologist at the Royal Marsden NHS Foundation Trust, said: “These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy.
“This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.”
